ABSTRACT Systemic, splanchnic, and renal hemodynamics, intravascular volume, and reflexive and endocrine changes were measured before and after a single dose of fenoldopam, a novel antihypertensive agent that acts through stimulation of specific dopamine receptors. A 13% reduction in mean arterial pressure was mediated by a fall in total peripheral resistance associated with an increase in cardiac index, heart rate, stroke volume, left ventricular ejection rate, and circumferential fiber shortening. Renal blood flow increased, thereby reducing the renal vascular resistance by more than 40%. In contrast, splanchnic hemodynamics failed to change. Likewise, there were no changes in intravascular volume, plasma renin activity, or norepinephrine, serum aldosterone, or prolactin levels. Circulation 69, No. 6, 1142No. 6, -1145No. 6, , 1984 THE KIDNEY has been said to be the primary site that both initiates the hypertensive process1 2 and is affected by hypertensive vascular disease. Thus arterial pressure may become elevated by an altered renal excretory "set point" that requires a higher perfusion pressure to excrete its sodium load, perhaps because of afferent glomerular arteriolar constriction.2 3 In contrast, as a result of the systemic arteriolar constriction, blood flow to the kidney may be diminished.`' Therefore a vasodilating agent, preferably with greater effects on the kidney, should be particularly useful in the treatment of patients with essential hypertension.
THE KIDNEY has been said to be the primary site that both initiates the hypertensive process1 2 and is affected by hypertensive vascular disease. Thus arterial pressure may become elevated by an altered renal excretory "set point" that requires a higher perfusion pressure to excrete its sodium load, perhaps because of afferent glomerular arteriolar constriction.2 3 In contrast, as a result of the systemic arteriolar constriction, blood flow to the kidney may be diminished.`' Therefore a vasodilating agent, preferably with greater effects on the kidney, should be particularly useful in the treatment of patients with essential hypertension.
Fenoldopam, a benzazepine derivative, is a novel antihypertensive agent with selective renal vasodilating properties. Preliminary studies in animals9 10 and patients"1 have indicated that it acts through stimulation of specific postsynaptic dopamine receptors in the renal vascular bed. However, unlike dopamine, higher doses of fenoldopam do not seem to increase either blood pressure or heart rate.9 This study was designed to determine the systemic and regional hemodynamic, cardiac, reflexive, and biochemical effects of a single oral dose of fenoldopam in patients with essential hypertension.
Materials and methods
Fourteen patients (10 men and four women) with mild established essential hypertension were included in this study. All had either never received antihypertensive therapy or had therapy discontinued at least 4 weeks before entering the study. Detailed clinical evaluation did not reveal any secondary cause for the hypertension or any concomitant disorders. 12 Each subject provided informed consent to a protocol previously approved by our institution's review committee.
All patients had a supine diastolic pressure (phase V of Korotkoff sounds) consistently above 90 mm Hg but not exceeding 120 mm Hg. Systemic and regional hemodynamics together with M mode echocardiograms, electrocardiograms, and blood samples for measurement of plasma renin activity and norepinephrine, serum aldosterone, and prolactin levels were obtained before (after placebo) and 1 hr after the oral administration of fenoldopam (50 [n = 5] or 100 mg [n = 9]). Systemic and regional hemodynamics were determined by methods previously reported in detail.12 Intra-arterial and venous pressures were monitored continuously. Cardiac output was measured in triplicate by the indocyanine green dye method (5 mg), with patients supine and in the postabsorptive state after an overnight fast.
Additionally, hemodynamic responses were assessed after 45 degree "head up" tilt and isometric exercise. 12 Arterial pressure and heart rate responses were also recorded during the Valsalva maneuver. '3 Renal plasma flow was determined by the single injection clearance of 131j para-aminohippurate. 12 Splanchnic blood flow was estimated by injecting 50 mg of indocyanine green dye, as previously reported. 12 Renal and splanchnic vascular resistances were calculated by dividing the mean arterial pressure by the respective regional blood flow measurement. Plasma vol- or dose-by-treatment interaction for any of the variables. Treatment with fenoldopam reduced mean arterial pressure in all patients by 13% (figure 1), and this was associated with a fall in total peripheral resistance and an increase in cardiac index, heart rate, stroke volume, and left ventricular ejection rate (table 2) . Renal blood flow increased, and as a result renal vascular resistance fell by 41% (figure 1). In contrast, there were no significant changes observed in splanchnic blood flow (table 2). The fall in pressure was asso- 
Discussion
The results of this study show that the antihypertensive effect of fenoldopam, a postsynaptic dopaminereceptor agonist, was mediated by a reduction of total and renal vascular resistances. An increase in cardiac index, stroke volume, heart rate, and left ventricular ejection rate occurred concomitantly.
The results of previous studies have shown that small doses of dopamine stimulate specific receptors in the renal vasculature that result in vasodilation. [19] [20] [21] [22] This effect is specifically antagonized by compounds such as bulbocapnine and metoclopramide. 20 22-24 However, in those studies higher doses of dopamine increased blood pressure (by augumenting total vascular resistance), heart rate, and contractile force through stimulation of a-and ,3-adrenergic receptors, respectively.21 22 Although dopamine is active only when administered intravenously, fenoldopam was highly effective in all patients when administered orally, reducing arterial pressure and total peripheral and renal vascular resistances. The findings of previous studies in animals have shown fenoldopam to decrease renal vascular resistance and to increase renal blood flow through a dopamine-like action without affecting peripheral a-and ,3-receptors.9 Moreover, renal function studies in normal subjects have shown that 1 hr after the administration of fenoldopam (either 50 or 100 mg), renal blood flow increases by 15% and 24%, respectively, without any changes in glomerular filtration rate. In addition, these effects were partially blocked by metoclopramide, demonstrating a specific action of fenoldopam on dopamine receptors.
As we have shown, fenoldopam also produces an increase in renal blood flow in patients with essential hypertension, which exceeds that observed in normal subjects. However, the increased renal blood flow cannot solely account for the augmented cardiac output observed in these patients. Thus, in addition to its dopamine-like action, fenoldopam may exert some other vasodilating effect. Nevertheless, it has been demonstrated that an increase in renal vascular resistance is a fundamental abnormality either in the pathogenesis or pathophysiology of essential hypertension6; therefore, an agent that can reverse this abnormality should be of great therapeutic importance.
The changes in cardiac index, heart rate, left ventricular ejection rate, and velocity of circumferential fiber shortening observed with fenoldopam can be explained by an increase in contractility related to a reflex stimulation of the heart. This could be the result of the reduced pressure sensed by the baroreceptors, diminished ventricular afterload, or a direct inotropic and chronotropic action of the drug. Previous studies demonstrated that fenoldopam does not, in itself, have a positive inotropic effect on a papillary muscle preparation.9 Surprisingly, despite the increased heart rate and cardiac output, plasma norepinephrine levels were not increased significantly. This finding contrasts with 26 The mechanism of this observation is unknown, although it could have resulted from an agonistic action of the agent on dopamine receptors of presynaptic nerve terminals.
Fenoldopam did not alter serum prolactin levels. The release of prolactin from the anterior pituitary is regulated by an inhibitory dopamine receptor. 21 There is no evidence that this receptor is associated with the stimulation of adenylate cyclase or accumulation of intracellular cyclic AMP, and therefore it has been classified as a subtype of dopamine receptor that is different from the vascular dopamine receptor.21 27 Our finding agrees with those of previous studies showing no changes in prolactin levels9 after fenoldopam administration.
Although no side effects were seen after fenoldopam administration, transient T wave changes were observed in nine patients (decreased voltage) without associated chest pain or enzyme changes. We cannot explain these changes, although they could be related to the cardiac stimulation produced by fenoldopam, since the heart rate and electrocardiograms returned to pretreatment levels the next day. These changes were unrelated to the dose administered. Similar T wave changes have been reported after the administration of another vasodilator, hydralazine.21
In conclusion, fenoldopam was a rapidly acting, orally effective vasodilator that reduced arterial pressure by stimulation of dopamine receptors, producing a fall in total peripheral resistance that was most noted in the renal circulation.
